Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q4 FY22 results · Jan–Mar 2022
Panacea Biotec reported revenue from operations of ₹140.73 crore (down 16.4% from Q4 FY21) and net profit of ₹1,237.47 crore for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 140.73 | 168.27 | −16.4% | 155.88 | −9.7% |
| Other income | 4.05 | 4.90 | −17.3% | 1.66 | +144.0% |
| Total income | 144.78 | 173.17 | −16.4% | 157.54 | −8.1% |
| Profit before tax | 1,608.26 | (52.65) | Turned profit | (49.16) | Turned profit |
| Net profit for the period | 1,237.47 | (54.14) | Turned profit | (49.20) | Turned profit |
| EPS, basic (₹) | 202.03 | (8.84) | Turned profit | (8.03) | Turned profit |
| Net margin (%) | 879.3 | -32.2 | -31.6 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 41.50 | 79.86 | −48.0% | 38.48 | +7.8% |
| Other income | 2.57 | 7.75 | −66.8% | 2.38 | +8.0% |
| Total income | 44.07 | 87.61 | −49.7% | 40.86 | +7.9% |
| Profit before tax | (25.31) | (16.79) | Loss widened | (22.43) | Loss widened |
| Net profit for the period | (25.31) | (18.31) | Loss widened | (22.43) | Loss widened |
| EPS, basic (₹) | (4.13) | (2.99) | Loss widened | (3.66) | Loss widened |
| Net margin (%) | -61.0 | -22.9 | -58.3 |
Consolidated
- Filed with BSE
- 23 May 2022, 16:00 IST
- Board meeting
- 18 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 23 May 2022, 16:00 IST
- Board meeting
- 18 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE